Marcia M Russell1, Patricia A Ganz, Samia Lopa, Greg Yothers, Clifford Y Ko, Amit Arora, James N Atkins, Nathan Bahary, Gamini S Soori, John M Robertson, Janice Eakle, Benjamin T Marchello, Timothy F Wozniak, Robert W Beart, Norman Wolmark. 1. *National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers, Pittsburgh, PA †David Geffen School of Medicine at UCLA, VA Greater Los Angeles Healthcare System, Los Angeles, CA ‡UCLA Schools of Medicine & Public Health and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA §University of Pittsburgh Graduate School of Public Health Department of Biostatistics, Pittsburgh, PA ∥UCLA, Los Angeles, CA ¶Kaiser Permanente Oncology Clinical Trials, Northern California, Vallejo, CA **Southeast Cancer Control Consortium CCOP, Goldsboro, NC ††University of Pittsburgh Medical Center, Pittsburgh, PA ‡‡Missouri Valley Cancer Consortium CCOP, Omaha, NE §§Beaumont Hospital System, Royal Oak, MI ∥∥Florida Cancer Specialists, Sarasota, FL ¶¶Montana Cancer Consortium, Billings, MT ***Helen F. Graham Cancer Center, Newark, DE †††Glendale Memorial Hospital and Health Center, Glendale, CA ‡‡‡Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA.
Abstract
OBJECTIVE:National Surgical Adjuvant Breast and Bowel Project (NSABP) R-04 was a randomized controlled trial of neoadjuvant chemoradiotherapy in patients with resectable stage II-III rectal cancer. We hypothesized that patients who underwent abdominoperineal resection (APR) would have a poorer quality of life than those who underwent sphincter-sparing surgery (SSS). METHODS: To obtain patient-reported outcomes (PROs) we administered two symptom scales at baseline and 1 year postoperatively: the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and the European Organization for the Research and Treatment of Cancer module for patients with Colorectal Cancer Quality of Life Questionnaire (EORTC QLQ-CR38). Scoring was stratified by nonrandomly assigned definitive surgery (APR vs SSS). Analyses controlled for baseline scores and stratification factors: age, sex, stage, intended surgery, and randomly assigned chemoradiotherapy. RESULTS: Of 1,608 randomly assigned patients, 987 had data for planned analyses; 62% underwent SSS; 38% underwent APR. FACT-C total and subscale scores were not statistically different by surgery at 1 year. For the EORTC QLQ-CR38 functional scales, APR patients reported worse body image (70.3 vs 77.0, P = 0.0005) at 1 year than did SSS patients. Males undergoing APR reported worse sexual enjoyment (43.7 vs 54.7, P = 0.02) at 1 year than did those undergoing SSS. For the EORTC QLQ-CR38 symptom scale scores, APR patients reported worse micturition symptoms than the SSS group at 1 year (26.9 vs 21.5, P = 0.03). SSS patients reported worse gastrointestinal tract symptoms than did the APR patients (18.9 vs 15.2, P < 0.0001), as well as weight loss (10.1 vs 6.0, P = 0.002). CONCLUSIONS:Symptoms and functional problems were detected at 1 year by EORTC QLQ-CR38, reflecting different symptom profiles in patients who underwent APR than those who underwent SSS. Information from these PROs may be useful in counseling patients anticipating surgery for rectal cancer.
RCT Entities:
OBJECTIVE: National Surgical Adjuvant Breast and Bowel Project (NSABP) R-04 was a randomized controlled trial of neoadjuvant chemoradiotherapy in patients with resectable stage II-III rectal cancer. We hypothesized that patients who underwent abdominoperineal resection (APR) would have a poorer quality of life than those who underwent sphincter-sparing surgery (SSS). METHODS: To obtain patient-reported outcomes (PROs) we administered two symptom scales at baseline and 1 year postoperatively: the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and the European Organization for the Research and Treatment of Cancer module for patients with Colorectal Cancer Quality of Life Questionnaire (EORTC QLQ-CR38). Scoring was stratified by nonrandomly assigned definitive surgery (APR vs SSS). Analyses controlled for baseline scores and stratification factors: age, sex, stage, intended surgery, and randomly assigned chemoradiotherapy. RESULTS: Of 1,608 randomly assigned patients, 987 had data for planned analyses; 62% underwent SSS; 38% underwent APR. FACT-C total and subscale scores were not statistically different by surgery at 1 year. For the EORTC QLQ-CR38 functional scales, APR patients reported worse body image (70.3 vs 77.0, P = 0.0005) at 1 year than did SSSpatients. Males undergoing APR reported worse sexual enjoyment (43.7 vs 54.7, P = 0.02) at 1 year than did those undergoing SSS. For the EORTC QLQ-CR38 symptom scale scores, APR patients reported worse micturition symptoms than the SSS group at 1 year (26.9 vs 21.5, P = 0.03). SSSpatients reported worse gastrointestinal tract symptoms than did the APR patients (18.9 vs 15.2, P < 0.0001), as well as weight loss (10.1 vs 6.0, P = 0.002). CONCLUSIONS: Symptoms and functional problems were detected at 1 year by EORTC QLQ-CR38, reflecting different symptom profiles in patients who underwent APR than those who underwent SSS. Information from these PROs may be useful in counseling patients anticipating surgery for rectal cancer.
Authors: Suzanne K Chambers; Xingqiong Meng; Pip Youl; Joanne Aitken; Jeff Dunn; Peter Baade Journal: Qual Life Res Date: 2011-12-27 Impact factor: 4.147
Authors: Michael S Kasparek; Imran Hassan; Robert R Cima; Dirk R Larson; Rachel E Gullerud; Bruce G Wolff Journal: Dis Colon Rectum Date: 2012-02 Impact factor: 4.585
Authors: A S Allal; S Bieri; A Pelloni; V Spataro; S Anchisi; P Ambrosetti; M A Sprangers; J M Kurtz; P Gertsch Journal: Br J Cancer Date: 2000-03 Impact factor: 7.640
Authors: Alexander T Hawkins; Katherine Albutt; Paul E Wise; Karim Alavi; Ranjan Sudan; Andreas M Kaiser; Liliana Bordeianou Journal: J Gastrointest Surg Date: 2018-04-16 Impact factor: 3.452
Authors: Kemi M Doll; Emma L Barber; Jeannette T Bensen; Matthew C Revilla; Anna C Snavely; Antonia V Bennett; Bryce B Reeve; Paola A Gehrig Journal: Am J Obstet Gynecol Date: 2016-04-27 Impact factor: 8.661
Authors: Lisa J Herrinton; Andrea Altschuler; Carmit K McMullen; Joanna E Bulkley; Mark C Hornbrook; Virginia Sun; Christopher S Wendel; Marcia Grant; Carol M Baldwin; Wendy Demark-Wahnefried; Larissa K F Temple; Robert S Krouse Journal: CA Cancer J Clin Date: 2016-03-21 Impact factor: 508.702
Authors: Patricio B Lynn; Lindsay A Renfro; Xiomara W Carrero; Qian Shi; Paul L Strombom; Oliver Chow; Julio Garcia-Aguilar Journal: Dis Colon Rectum Date: 2017-05 Impact factor: 4.585